Bristol Myers wins a big bet as their PhIII autoimmune drug beats a blockbuster sold to Amgen for $13B-plus

Bristol Myers Squibb $BMY bet big on a Phase III psoriasis program for its TYK2 contender deucravacitinib (BMS-986165). And today they’re declaring their heavyweight contender the champ in a toe-to-toe bout with Amgen’s oral blockbuster Otezla, a must-win over a Celgene drug that Bristol Myers agreed to divest in order…